Quantumup
Nov 10, 11:41 AM
$FTH all a/o y'day
BTIG: Buy-
$55 ~views the dip as a buying opp.
[CELC RLAY NVS RHHBY AZN]
H.C. Wainwright: Buy-
$60 ~would use weakness to build positions—calls selloff overdone.
Lucid Capital: Buy-
$59 ~views selloff as disproportionate—while the headline ORR was broadly in the range of emerging ADC's rather than clearly superior, the broader dataset is more encouraging, with 16 pts remaining on Tx.
TD Cowen: Buy: PIKTOR achieved a 33% ORR and 7.4-month mPFS, clearly exceeding the chemo bar (~15% ORR; 3-4 months). While ORR missed investors' 40% bar, it could improve, and mPFS offsets as it is competitive with sac-TMT. We believe the orthogonal MoA supports Phase III development and an attractive 2L+ EC role. The low hyperglycemia (12%) and stomatitis (21%) rates derisk the larger BC opportunity.
0 replies